NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Nurix Therapeutics, Inc. NRIX
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$84.0M
▲ 54.0% vs FY2024
EPS · FY25
$-3.05
Dividend / sh · FY25
$0.00
Payout · FY25
—
ROE · FY25
-49.6%
Net margin · FY25
-314.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 84.0M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 315 cents on every revenue dollar this year.
Per share
USD -3.05
Diluted EPS, FY2025
EPS
Dividend
The company pays no cash dividend.
Profitability
-49.6%
Return on equity, FY2025
ROE
Operating margin-340.2%
Net margin-314.9%
Return on assets-39.0%
Each USD of equity lost 50 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+36.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+29.5%
+36.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 688.1M
total assets, end of FY2025
Total assetsUSD 688.1M
EquityUSD 538.7M
CashUSD 247.0M
Current ratio7.02×
Equity funds 78% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.1
0.1
0.1
0.0
0.0
0.0
0.0
Operating income $B
−0.3
−0.2
−0.2
−0.2
−0.1
−0.1
−0.0
EBITDA $B
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
Net income $B
−0.3
−0.2
−0.1
−0.2
−0.1
−0.0
−0.0
EPS, diluted $
−3.05
−2.88
−2.65
−3.71
−2.73
−2.76
−6.59
Dividend / sh $
0.00
0.00
·
·
·
0.00
0.00
Payout %
·
·
·
·
·
·
·
ROE %
−49.6
−53.2
−57.1
−55.8
−37.1
−37.2
·
Shares out B
0.10
0.08
0.05
0.05
0.04
0.04
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed